Driehaus Capital Management’s Hemab Therapeutics COAG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.8M Sell
708,166
-7,625
-1% -$335K 0.15% 191
2026
Q2
$26.3M Buy
+715,791
New +$19.8M 0.15% 197

Other funds holding COAG

Driehaus Capital Management's COAG Position: Q3 2026 in Review

Driehaus Capital Management reduced its Hemab Therapeutics (COAG) stake by 1.1% in Q3 2026, selling an estimated $335K and leaving 708,166 shares worth $21.8M. The position accounts for 0.15% of the portfolio, ranked #191.

Driehaus Capital Management first reported a position in COAG in Q2 2026 and has held it in 2 quarters since. The position peaked at $26.3M in Q2 2026. 89 funds tracked by Wall St. Rank hold COAG as of Q3 2026.

  • Driehaus Capital Management held 708,166 shares of Hemab Therapeutics worth $21.8M as of Q3 2026.
  • Driehaus Capital Management sold 7,625 Hemab Therapeutics shares in Q3 2026, an estimated $335K.
  • Hemab Therapeutics made up 0.15% of Driehaus Capital Management's portfolio in Q3 2026, its #191 holding.
  • Driehaus Capital Management first reported a position in Hemab Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Driehaus Capital Management's Hemab Therapeutics position peaked at $26.3M in Q2 2026.
  • 89 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.

Based on Driehaus Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.